#RareDiseases #Biotech #DrugDevelopment
fortune.com
The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients | Fortune
For patients living with rare and neglected diseases, the next breakthrough treatment might already be sitting in a pharmaceutical company's filing cabinet.
#CancerResearch #DrugDevelopment #ProteinBiology
news.harvard.edu
Unlocking hidden pocket on a billion‑dollar drug target -- Harvard Gazette
Scientists identify path toward making cancer drugs safer and more selective
For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs.
#Pharmaceuticals #ClinicalTrials #DrugDevelopment
www.nasdaq.com
Crinetics To Provide Update On PALSONIFY And Topline Results From Phase 2 Trial Of Atumelnant In CAH
(RTTNews) - Crinetics Pharmaceuticals, Inc. (CRNX) is scheduled to host a conference call to provide an update on its lead drug PALSONIFY's commercialisation and disclose topline results from the fourth cohort of its Phase 2 trial of Atumelnant in congenital adrenal hyperplasia or CAH, today.
